Mirtazapine (Mirtazapinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antidepressants

Included in the formulation
  • Kaliksta®
    pills inwards 
    Beluga, medicines and cosmetics.     Croatia
  • Mirzaten
    pills inwards 
    KRKA, dd, Novo mesto, AO    
  • Mirzaten® Ku-Tab
    pills n / az. 
    KRKA, dd, Novo mesto, AO    
  • Mirtazapine Canon
    pills inwards 
    CANONFARMA PRODUCTION, CJSC     Russia
  • Mirtazonal
    pills n / az. 
    AKTAVIS GROUP, AO     Iceland
  • Mirtazonal
    pills inwards 
    AKTAVIS GROUP, AO     Iceland
  • Myrtlean
    pills inwards 
    VALEANT, LLC     Russia
  • Noxibel®
    pills inwards 
    Laboratorios Bago S.A.     Argentina
  • Remeron®
    pills inwards 
    Organon, N.V.     Netherlands
  • Esprital®
    pills inwards 
    Zentiva c.s.     Czech Republic
    • АТХ:

    N.06.A.X.11   Mirtazapine

    Pharmacodynamics:

    Enhancement of central adrenergic and serotonergic transmission, possibly as a result of blockade of presynaptic α2adrenoreceptors. Antidepressant effect is manifested after 1-2 weeks of treatment. Sedative action is due to blockade of histamine H1receptors. Blocks serotonin 5-HT2- and 5-HT4receptors and has a peripheral α1-adrenoblocking action.

    Pharmacokinetics:

    Relationship with plasma proteins 85%. Maximum concentration after 2 hours. Biotransformation in the liver to active metabolites. The half-life of men is 24 hours, for women 37 hours. Elimination by the kidneys (75%) and with feces (15%).

    Indications:

    Endogenous depression.

    Psychomotor retardation.

    Insomnia.

    Early awakening.

    Decreased body weight.

    Loss of interest in life.

    Suicidal thoughts and mood lability.

    ICD-10

    V.F30-F39.F32   Depressive episode

    V.F30-F39.F33   Recurrent depressive disorder

    V.F30-F39.F31.3   Bipolar affective disorder, current episode of mild or moderate depression

    V.F40-F48.F41.2   Mixed anxiety and depressive disorder

    V.F50-F59.F51.0   Insomnia inorganic etiology

    V.F60-F69.F69   Disorder of personality and behavior in adulthood, unspecified

    VI.G40-G47.G47.0   Disturbances of falling asleep and maintaining sleep [insomnia]

    XXI.Z80-Z99.Z91.5   In a personal history, self-harm

    XVIII.R40-R46.R46.4   Retardation and delayed reaction

    Contraindications:

    Individual intolerance.

    Hepatic and / or renal insufficiency.

    Pregnancy and breastfeeding.

    Childhood.

    Carefully:

    Prostate adenoma.

    Closed-angle glaucoma.

    Diabetes.

    Epilepsy.

    Organic lesions of the brain.

    Arrhythmias, angina pectoris, arterial hypotension, acute myocardial infarction.

    Pregnancy and lactation:

    FDA recommendation category C. It is not recommended to use during pregnancy and breastfeeding.

    Dosing and Administration:

    Inside, not liquid, before going to bed. The initial dose of 15 mg per day with a gradual increase in dose, depending on the effect and tolerability.

    Side effects:

    Apathy, anxiety, hypokinesis, or hyperkinesis, respiratory failure, swelling, agitation, frustration, skin rash.

    Rarely, agranulocytosis and neutropenia, impotence, menstrual irregularities, hallucinations, mania, emotional lability.

    Overdose:

    When an overdose is observed drowsiness, disorientation, tachycardia, amnesia. Treatment is symptomatic, there are no antidotes.

    Interaction:

    Alcohol or other drugs that depress the central nervous system - potentiation of CNS depression, respiration and hypotensive effect.

    MAO inhibitors - fever, convulsions, agitation, possible fatal outcome. Do not use simultaneously with MAO inhibitors and within 2 weeks after their withdrawal.

    Special instructions:

    When prescribing antidepressants, patients with schizophrenia or other psychotic disorders may increase psychotic symptoms. In the treatment of the depressive phase of bipolar affective psychosis, an affect inversion with the development of mania can be observed.

    Women of reproductive age need to use reliable methods of contraception.

    During treatment it is recommended to refrain from drinking alcohol.

    Instructions
    Up